

Marlborough, October 29, 2020

Sartorius to open new Customer Interaction Center in North America

- 40,000-square-foot Customer Interaction Center in Marlborough, Massachusetts
- 100 new jobs created from initiative
- Opening of first units early 2021

Sartorius, a leading international partner of life science research and the biopharmaceutical industry, is expanding its presence in Massachusetts with a North American Customer Interaction Center. Sartorius will be opening first units of the new 40,000-square-foot Customer Interaction Center in Marlborough in early 2021. "With our new site in Marlborough, we will be optimizing factory acceptance testing and commissioning of new bioprocess equipment supplied to the North American market. This investment will translate into tangible benefits for our customers, employees, suppliers, and the local community," said the President of Sartorius North America, Mary Lavin.

The new site will be a focal point for customers in what is now one of the world's largest development hubs for biopharmaceutical products and will create around 100 new jobs. These jobs will be in the engineering disciplines of process and mechanical design as well as in electrical and automation engineering. Additionally, Sartorius will be employing production technicians, customer service and support staff. This is the first time Sartorius will be designing, building and delivering industry-leading manufacturing solutions in North America for its North American customers.

The Customer Interaction Center initiative will enable Sartorius to scale up its operations and capabilities in the Boston biotech hub. The new site in Marlborough also will provide the capacity to support partners in the development and manufacture of COVID-19 vaccines and therapeutics.

A profile of Sartorius

The Sartorius Group is a leading international partner of life science research and the biopharmaceutical industry. With innovative laboratory instruments and consumables, the Group's Lab Products & Services Division concentrates on serving the needs of laboratories performing research and quality control at pharma and biopharma companies and those of academic research institutes. The Bioprocess Solutions Division with its broad product portfolio focusing on single-use solutions helps customers to manufacture biotech medications and vaccines safely and efficiently. The Group has been annually growing by double digits on average and has been regularly expanding its portfolio by acquisitions of complementary technologies. In fiscal 2019, the company earned sales revenue of some 1.83 billion euros. At the end of 2019, more than 9,000 people were employed at the Group's approximately 60 manufacturing and sales sites, serving customers around the globe.

Contact

Andre Hofmann
Corporate Communications
Phone: +49.551.308.5096
andre.hofmann@sartorius.com

Corris A. Little
Corporate Communications North America
Phone: +1.631. 690. 9936
corris.little@sartorius.com

Follow Sartorius on [Twitter @Sartorius_Group](#) and on [LinkedIn](#).